ArticleVirchows Archiv : an international journal of pathology2026
Comparison of biopsy gleason pattern 4 percentage and length in grade group 2 prostate cancer patients.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Quantification of biopsy Gleason pattern (GP) 4 contributes to risk assessment and supports clinical decision-making in Grade Group 2 (GG2) prostate cancer (PCa) patients. The optimal methodology for assessment of GP4 quantity is yet unclear. The objective of this study is to compare the mutual relation and performance of biopsy GP4 quantification methods to predict biochemical recurrence-free survival (BCRFS) after radical prostatectomy (RP). Ninety-four patients with biopsy GG2 PCa who underwent RP were included. We recorded overall GP4 percentage and cumulative GP4 length (mm) across all cores, as well as the maximum percentage and length within a single core. Quantification methods were compared using Spearman's rank correlation and Cox proportional hazard regression for BCRFS. All biopsy GP4 quantification methods were mutually correlated (rho coefficients varying from 0.655 to 0.935; P < 0.001), while correlation with GP4 percentage at RP was weak to moderate (rho coefficient range 0.260 to 0.326; P < 0.02). All biopsy GP4 quantification methods significantly predicted post-operative BCRFS. Absolute GP4 measures had better discriminative performance than percentages (cumulative GP4 length Hazard Ratio [HR] 1.14; 95% Confidence Interval [95% CI] 1.07-1.22; P < 0.001; c-index 0.711; overall GP4 percentage HR 1.05; 95% 1.01-1.09; P = 0.007; c-index 0.635). Adding GP3 percentage or length did not have added value (P > 0.5) for predicting BCRFS once absolute GP4 length was known. Absolute GP4 length (mm) in biopsy GG2 PCa patients has better predictive value for post-operative BCRFS than GP4 percentage. GP3 volume does not add to prediction once GP4 volume is known.
Indexed as
Identifiers
41964720What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.